Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$3.78M+49.18%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David H. Kirn
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 196
- Beta
- 2.73
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 2.32
Financials
Revenue
$3.78M+49.2%Net Income
$-72.94MEBITDA
$-74.94MFree Cash Flow
$-70.05MEPS (diluted)
$-1.04Shares Outstanding (diluted)
70.27M+1299.6%Operating Expenses
$80.81MCash & Debt
$361.33MRevenue by Segment (annual)
$85.21MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $85.21M | $-140.11M | $-2.42 |
| 2024 | $37.0K | $-160.87M | $-2.98 |
| 2023 | $20.72M | $-100.84M | $-2.58 |
| 2022 | $3.13M | $-107.49M | $-3.12 |
| 2021 | $18.04M | $-71.32M | $-2.46 |
| 2020 | $13.61M | $-56.69M | $-2.12 |
| 2019 | $6.99M | $-49.31M | $-2.00 |
| 2018 | $14.13M | $-9.55M | $-0.76 |
| 2017 | $5.79M | $-11.22M | $-0.76 |
Valuation
FDMThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·1d ago·Neutral
4DMT to Host Investor Day on October 21, 2026 Company to share insights on the advancing clinical profile and commercial vision for 4D-150 Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C.
View source ↗ - Newsglobenewswire.com·8d ago·Neutral
… for Second Large Market Retina Indication with Initiation of 4SIGHT in DME EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical tri…
View source ↗ - Newsseekingalpha.com·18d ago·Positive
4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript 4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·21d ago·Positive
4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript 4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·42d ago·Neutral
4DMT to Participate in Upcoming Investor Conferences EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in September:
View source ↗ - Newszacks.com·53d ago·Negative
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates 4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.04 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.98 per share a year ago.
View source ↗
Earnings
Tue, Nov 10(in 5 weeks)
Consensus estimate $-1.04 per share
Typical surprise -2.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-1.04 vs $-1.02miss
- Thu, May 7$-1.01 vs $-0.97miss
- Wed, Mar 18$0.43 vs $-0.53beat
- Mon, Nov 10$-1.01 vs $-1.02beat
- Mon, Aug 11$-0.98 vs $-0.88miss
- Thu, May 8$-0.86 vs $-0.84miss
Estimates and results for FDMT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by FDMT officers and directors.
- Bought
- —
- Sold
- $4.7m
0 trades
26 trades
- Bizily Scottsold
- Kirn Davidsold
- Bizily Scottsold
- Kirn Davidsold
- Kirn Davidsold
- Bizily Scottsold
- Bizily Scottsold
- Kirn Davidsold
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in FDMT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.